Jarden analyst Steven Wheen maintained a Buy rating on Telix Pharmaceuticals Ltd. (TLPPF – Research Report) on April 18 and set a price target of A$13.52. The company’s shares closed last Friday at $8.83.
According to TipRanks, Wheen is a 4-star analyst with an average return of 10.7% and a 50.00% success rate. Wheen covers the Healthcare sector, focusing on stocks such as Ramsay Health Care, Cochlear Limited, and Telix Pharmaceuticals Ltd..
Telix Pharmaceuticals Ltd. has an analyst consensus of Strong Buy, with a price target consensus of $10.10, representing a 14.45% upside. In a report released on April 18, UBS also maintained a Buy rating on the stock with a A$19.30 price target.
The company has a one-year high of $9.15 and a one-year low of $5.30. Currently, Telix Pharmaceuticals Ltd. has an average volume of 6,421.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Telix Pharmaceuticals Ltd. (TLPPF) Company Description:
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer. Geographically, it operates in Australia, the United States, Belgium, and Japan.
Read More on TLPPF:
